CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
克服 B 细胞恶性肿瘤中抗 CD19 CAR-T 细胞疗法的耐药
英文原题：Overcoming resistance to anti-CD19 CAR T-cell therapy in B-cell malignancies.
查看英文原题
Overcoming resistance to anti-CD19 CAR T-cell therapy in B-cell malignancies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
抗 CD19 嵌合抗原受体（CAR）T 细胞疗法迅速改变了当前治疗模式，为原发难治或复发的 B 细胞非霍奇金淋巴瘤（r/r B-NHL）及 B 急性淋巴细胞白血病（r/r B-ALL）患者提供了更好的选择。然而，尽管疗效显著，部分 B 细胞恶性肿瘤患者在抗 CD19 CAR-T 治疗后仍有较高复发率，这是提高总体缓解率和长期结局的主要障碍。理解耐药机制对于改进现有 CAR-T 产品、优化其纳入当前治疗体系的方式，以及开发新型 CAR 策略至关重要。本文讨论限制 CAR-T 疗效并导致 CD19 阴性和 CD19 阳性复发的机制研究最新进展，并全面介绍目前可能克服这些障碍的策略。
展开英文摘要原文
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy has rapidly changed current treatment pattern, providing a better option for individuals with primary refractory or relapsed B-cell non-Hodgkin lymphoma (r/r B-NHL) and B-cell acute lymphoblastic leukemia (r/r B-ALL).
However, despite the outstanding efficacy, a high relapse rate is still found in some B-cell malignancies after anti-CD19 CAR T-cell therapy, which emerges as a main barrier for improving the overall response and long-term outcomes. Understanding the resistance mechanism is crucial to improve current CAR T products, better incorporate them into the current therapy system and develop novel CAR approaches.
Herein, we discuss the latest advances in understanding the mechanisms limiting efficacy of CAR T-cell therapy, resulting in CD19 negative (CD19 - ) and CD19 positive (CD19 + ) relapses.
We also provide a whole scenario of current potential strategies to overcome these barriers.
论文信息
- 作者
- Yang X、Wei J、Zhou J
- 单位
- Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.China
- 期刊
- Hematological oncology2022 Dec
- 原文标识
- PubMed 35635796 · DOI 10.1002/hon.3036